24 May, 2017
The stock was trading on below-average volume. Finally, Schwab Charles Investment Management Inc. boosted its position in Synergy Pharmaceuticals by 10.5% in the first quarter. In contrast, SGYP's 52 week high hovers at $7.15 with its current distance from 52 week high value is -45.17%. Lord Abbett And Limited Com reported 335,000 shares stake. It represents the location of the previous close relative to the price range over a set number of periods. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.07. The stock has "Neutral" rating by Citigroup on Wednesday, March 1.
Investors sentiment increased to 1.08 in Q4 2016. Its down 0.60, from 1.79 in 2016Q3. 62 funds opened positions while 56 raised stakes. 177,300 are owned by State Common Retirement Fund. Aperio Gp accumulated 21,252 shares. Moreover, Da Davidson And has 0% invested in MasTec, Inc. Northern holds 2.09M shares. Modera Wealth Lc owns 10,500 shares or 0.02% of their U.S. portfolio. Stifel Financial holds 0.03% of its portfolio in Ross Stores, Inc. The company have shares float of 216.93 million. Aqr Capital Management Ltd Llc holds 0% or 25,940 shares in its portfolio. One Natl Association reported 3,847 shares stake. First Personal Service holds 303 shares. Mu Communication accumulated 67,100 shares. The current consensus recommendation provided by covering analysts is 2.00. MasTec has $57 highest and $16 lowest target. Its share have plunged by -11.64% in percentage terms since the start of the year - and added 2.35% in the last month. The overall market is assigned a beta of 1.0. The stock of MasTec, Inc. The stock has "Buy" rating by Stifel Nicolaus on Monday, November 14.
Recent session action on shares of Synergy Pharmaceuticals Inc. Analysts set a 12-month price target of $5.88 a share. Analysts, on average, seem bullish as they suggest SGYP is worth $6.52 more, giving a target price of $10.44/share.
News coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has trended somewhat positive this week, AlphaOne reports. TH Capital reinitiated it with "Buy" rating and $9.5 target in Thursday, October 29 report. Finally, Canaccord Genuity reiterated a "buy" rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a report on Saturday, January 28th.
In the quarter ending September 2016, Synergy Pharmaceuticals Inc. delivered an even larger earnings beat. The stock has "Buy" rating by H.C. Wainwright on Thursday, October 1. SGYP has outperformed the S&P 500 by 5.83.
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The stock's market cap is $876.18 million. The Company's principal product line is its coffee fruit wellness drinks. It now has negative earnings.
A number of research firms recently commented on SGYP. Since an alpha above 1 hints at more gains, investors can predict some further rally scope. Its up 0.24, from 0.84 in 2016Q3. At the time of writing, Synergy Pharmaceuticals Inc. Its 228.98 million shares were outstanding. Schwab Charles Investment Mgmt Inc accumulated 778,899 shares. It improved, as 41 investors sold ROST shares while 240 reduced holdings. 52,500 were accumulated by Cheyne Mngmt (Uk) Llp. Metropolitan Life Insurance Co. Sequoia Fincl Advsrs Ltd Liability accumulated 18,226 shares. The analysts estimated sales for the higher end at 3 million and lower end at 1.26 million while the year ago reported sale was 0 million.
WARNING: "Synergy Pharmaceuticals Inc (SGYP) Trading Down 6.3% on Disappointing Earnings" was published by Chaffey Breeze and is the sole property of of Chaffey Breeze.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
